Can a Foreign Company Sponsor an FDA IDE? No — Here Is the Rule

The Rule: A Foreign Company Cannot Sponsor an FDA IDE Study

Under 21 CFR 812.18(a), a company outside the United States cannot itself sponsor an FDA Investigational Device Exemption (IDE) study, full stop. This is a hard statutory requirement, not a procedural preference, and no amount of creative application language will change it. If your headquarters is in Germany, South Korea, Israel, or anywhere else outside US borders, you must route your IDE sponsorship through a qualifying US entity before FDA will accept your submission.

To state it plainly: FDA requires that the sponsor of an IDE be located in the United States. A non US manufacturer that wishes to conduct a clinical study under an IDE cannot hold that IDE directly. The obligation to maintain the IDE, communicate with FDA, and assume regulatory accountability must sit with a US-based entity. Foreign manufacturers who skip this step face outright rejection of their IDE application.

What FDA Actually Says

FDA addresses this directly in its IDE Frequently Asked Questions. The agency states: 'The sponsor must be located in the United States.' That sentence is unambiguous. It does not say the sponsor must have a US office, a US bank account, or a US employee on staff. It says the sponsor must be located in the United States, which FDA interprets to mean the sponsoring entity itself must be a US legal entity with a US address of record.

A Commonly Misstated Rule

This requirement is one of the more frequently mishandled points in IDE regulatory strategy. It is worth noting, without attributing it to any specific source, that automated tools and general-purpose information resources have answered this question incorrectly before being corrected elsewhere. Founders and regulatory affairs professionals sometimes receive confidently worded guidance suggesting that a foreign parent company can sponsor an IDE with a US-based point of contact or a US agent. That is incorrect. A US agent is not a US sponsor. The distinction matters enormously when FDA reviews your IDE application and when your study comes under agency scrutiny during or after enrollment.

If you have received conflicting information on this point, the safest step is to review 21 CFR Part 812 directly and consult a regulatory professional who works with IDEs routinely.

Three Compliant Structures for Foreign Manufacturers

Foreign manufacturers are not locked out of the US IDE pathway. They simply must use one of three recognized structures to establish compliant US sponsorship. Each carries different cost and time implications.

• A US subsidiary: Forming a US legal entity (typically a corporation or LLC) that holds the IDE directly. This structure gives the foreign parent the most control but requires formation costs, registered agent fees, and a minimum of several weeks to establish properly before an IDE can be filed.
• A US physician acting as sponsor investigator: Under 21 CFR 812.3(m), a licensed US physician can serve as both sponsor and investigator, assuming full regulatory responsibility. This can move quickly when the right clinical partner is identified, but it places significant regulatory burden on the physician and is most practical for nonsignificant risk or early feasibility studies where a single site is involved.
• A contracted US sponsor of record: Engaging a regulatory consulting or contract organization that assumes the IDE sponsorship role on behalf of the foreign manufacturer under a formal agreement. This is typically the fastest path to IDE submission readiness, with engagement timelines measured in days rather than months, though ongoing retainer or service fees apply for the duration of the study.

How ADB Consulting Supports Foreign Manufacturers

ADB Consulting and CRO Inc. serves as a contracted US Sponsor of Record for foreign medical device manufacturers seeking FDA IDE authorization, assuming the regulatory obligations that FDA requires while working closely with your team throughout the study lifecycle.

Our work includes helping your team assess IDE eligibility, review your device classification and risk determination, and prepare a complete IDE submission package that meets FDA's requirements under 21 CFR Part 812. We do not promise specific FDA outcomes, but we bring deep familiarity with the IDE pathway to every engagement.

Learn more about our US Sponsor of Record service at adbccro.com/us-sponsor.

Reviewed October 18, 2026 by ADB's regulatory team.

Frequently Asked Questions

What does a US Sponsor of Record actually do?

A US Sponsor of Record assumes the regulatory obligations that FDA assigns to the IDE sponsor under 21 CFR Part 812. That includes maintaining the IDE, submitting required reports, communicating with FDA on your behalf, and ensuring that the study is conducted in accordance with the approved IDE. The foreign manufacturer retains operational involvement in the study; the sponsor of record holds the regulatory accountability that FDA requires to be located in the United States.

Can a US regulatory consultant serve as our sponsor of record without being a clinical research organization?

Yes. FDA's IDE regulations identify the sponsor by legal responsibility, not by company type. A qualified regulatory consulting firm that accepts the sponsorship obligations in writing and maintains a US address of record can serve as sponsor of record. ADB Consulting and CRO Inc. is structured to take on this role and has experience preparing and managing IDE submissions for non US device manufacturers.

How do we get started if we are ready to pursue an IDE?

The first step is a discovery conversation to assess your device, your study design, and your timeline. From there, our team can review your existing documentation, identify gaps relative to 21 CFR Part 812, and prepare a roadmap for IDE submission. Book a free discovery call with Andre Butler and the ADB team at adbccro.com to start that conversation.

If this applies to your program, our US Sponsor of Record program walks through the process in detail.